{"id":"W4415368586","doi":"10.1016/j.annonc.2025.10.006","title":"Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Takeda Oncology; Chugai Pharmaceutical; Weill Cornell Medical College; Daiichi Sankyo Company; Pfizer Japan; Unicancer; Ipsen; Eisai; Relay Therapeutics; Seagen; European Social Fund; Puma Biotechnology; Pfizer; Fondazione Internazionale Menarini; Genentech; Lilly Deutschland; Veracyte; Mersana Therapeutics; Helsinn; Les Laboratories Pierre Fabre; Menarini Silicon Biosystems; Friedrich-Alexander-Universität Erlangen-Nürnberg; Eisai Korea; Ipsen Biopharmaceuticals; F. Hoffmann-La Roche; Daiichi Sankyo Europe; Novartis Foundation; Gilead Sciences; Sanofi; Celgene; Universität Ulm; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Emory University","keywords":"Clinical trial; Disease; Breast cancer; Safety profile; MEDLINE","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00177917,0.0004599318,0.001301482,0.0002508812,0.0002784015,0.001098507,0.00036219,0.0007197195,0.001634782],"category_scores_gemma":[0.002890356,0.0002076391,0.002298182,0.0003867722,0.0003588238,0.0008121062,0.000378019,0.001889714,0.0001908004],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005418081,"about_ca_system_score_gemma":0.0004700146,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006330576,"about_ca_topic_score_gemma":0.001729428,"domain_scores_codex":[0.9990976,0.0004369064,0.00009969454,0.0001306493,0.0001048346,0.0001304038],"domain_scores_gemma":[0.9984227,0.0006002968,0.0005159734,0.00008410656,0.00008118217,0.0002957097],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5402105,0.002649269,0.3310367,0.002115162,0.02632829,0.0007201274,0.00034744,0.004549909,0.003587516,0.0008911305,0.006397319,0.08116675],"study_design_scores_gemma":[0.1394942,0.07542929,0.7418368,0.0006756519,0.02089117,0.002040774,0.000483765,0.005275346,0.001652104,0.001916604,0.0100872,0.0002171338],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849277,0.01093978,0.0001558926,0.0005178266,0.0001620032,0.00009222672,0.001183987,0.00001129582,0.002009307],"genre_scores_gemma":[0.995111,0.002117218,0.0001388982,0.0003909978,0.0002038263,0.00009806384,0.001486132,0.00000381723,0.0004499978],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00177917,"threshold_uncertainty_score":0.009409249,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02773852152055462,"score_gpt":0.3571305366704038,"score_spread":0.3293920151498492,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}